Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PF-06826647 in moderate to severe plaque psoriasis
2018-004669-16Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ropsacitinib in plaque psoriasis (3 arms), sponsored by Pfizer. Primary endpoint: Proportion of participants achieving PASI 90 at Week 16. Started Jul 2019; status: completed.
02
Drugs
ropsacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-004669-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004669-16.